colon cancer
Conditions
Interventions
Test group:Postoperative adjuvant chemotherapy plus infusion of NK cells derived from human umbilical cord blood
control group:Postoperative adjuvant chemotherapy
Sponsors
The Third Affiliated Hospital of Kunming Medical University (Yunnan Tumor Hospital)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 years old, both male and female; 2. The first diagnosis, without any anti-tumor treatment before surgery, was confirmed as colon adenocarcinoma by pathology after surgery, and the AJCC/UICC 8th edition was used to stage IIc-IIIc according to TNM; 3. No abnormality of heart, liver, kidney and coagulation function: total bilirubin (TIIAC) =1.5^9/L; platelet (PLT) count: >=10^9/L; hemoglobin (Hb) level >=90g/L; 5. ECOG score 0-1 points; 6. Those who have no intellectual or mental impairment, have normal language expression ability, have the ability to judge their own pain and general conditions, and can cooperatively evaluate the content of pain and quality of life; 7. Those who voluntarily participated in this study, signed the informed consent form, had good compliance, and agreed to follow up for 2 years.
Exclusion criteria
Exclusion criteria: 1. Have a history of organ transplantation, etc.; 2. Combined with other tumor subjects; 3. Subjects with active tuberculosis and other serious infectious diseases; 4. Patients who are allergic to albumin; 5. Subjects with a history of prescription drug abuse, illicit drug abuse, and alcohol abuse within 6 months before screening; 6. Abuse of alcohol or drugs; 7. Pregnancy or lactation; 8. Participated in other clinical studies within 3 months before screening; 9. Any situation that the investigator believes may lead to participation in the study not in the best interests of the subjects or may prevent, limit or confound the safety or efficacy assessment prescribed by the protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence and metastasis rates; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of adverse events (AE) and serious adverse events (SAE);Immune function-related detecting;Tumor biomarkers (CEA);Evaluation of quality of life; | — |
Countries
China
Contacts
Public ContactDong Jian
The Third Affiliated Hospital of Kunming Medical University (Yunnan Tumor Hospital)
Outcome results
None listed